Switched from Mounjaro to Wegovy and it's not working — what the evidence says

What the trial data actually shows about switching between these two medicines

Tirzepatide and semaglutide are both GLP-1 receptor agonists, but they are not identical. Tirzepatide also activates the GIP receptor, giving it a dual mechanism that semaglutide does not have. In SURMOUNT-5 (a 72-week, open-label trial comparing tirzepatide directly against semaglutide 2.4mg in 751 adults with obesity) tirzepatide produced meaningfully greater average weight reduction. NICE's appraisal of tirzepatide (TA1026) acknowledges this advantage while noting that indirect comparisons carry limitations.

This matters when you switch direction. Moving from a dual-agonist to a single-agonist means your body is no longer receiving that second signal. That is not a flaw in Wegovy, it is simply a pharmacological difference. People who lost weight quickly on Mounjaro sometimes find Wegovy doesn't match that pace, particularly in the early months after switching.

There is also a dose-equivalence problem. A comparison between Mounjaro at, say, 10mg and Wegovy at 1.7mg is not like-for-like. Wegovy's standard maintenance dose is 2.4mg weekly; the newly approved 7.2mg pen, confirmed by the MHRA in April 2026, narrows the gap with tirzepatide considerably, but if you have not yet reached the maintenance dose, the medicine is still titrating, not at full effect.

How the two medicines compare on results and mechanism

Numbers from SURMOUNT-1 (NEJM) and the MHRA's April 2026 approval announcement for the 7.2mg pen. Trial populations and conditions differ; these figures reflect averages, not individual results.

For a fuller side-by-side look at the two treatments, the Wegovy vs Mounjaro comparison page covers mechanism, eligibility and cost context in detail. And if cost played a role in the switch, the cost comparison explains what the price difference actually reflects clinically.

Why Wegovy might not be working after the switch, common clinical reasons

A stall is rarely one thing. The most frequent reasons a prescriber would explore include:

Dose position. If you switched to Wegovy's starting dose and haven't yet reached maintenance, you are comparing a peak dose of one medicine against a titration dose of another. That is rarely a fair test. Timing the switch and the dose ladder matters more than most people realise.

Receptor adaptation. Months on a dual-agonist may mean your appetite responses were calibrated to two simultaneous signals. The adjustment period on a single-agonist can be longer than the standard 4-week titration window suggests.

Lifestyle drift. GLP-1 medicines reduce appetite; they work alongside a reduced-calorie diet and increased activity. If either shifted during the switch period, the medicine carries less of the total effect. This is not a character failing, disruption during any change in treatment is normal.

Genuine lower response. Some people respond better to one mechanism than the other. That is a clinical fact, not a personal one. The question why Wegovy isn't working after Mounjaro has a clinical answer your prescriber can work through with you.

It is also worth reading about what happens when weight returns after stopping either treatment, that evidence shapes how prescribers think about continuity and switching decisions.

What to do if you're not getting the results you expected

Do not stop or adjust your dose without speaking to your prescriber first. That instruction is not bureaucratic caution, a too-fast change can worsen the side-effect profile and makes it harder to tell what is actually happening.

Bring your prescriber the specifics: your current dose, how long you have been on it, your weight at the point of switching, and your weight now. A structured conversation is far more useful than a self-adjusted plan. If you are with a service that offers same-day clinical review, that conversation can happen quickly.

Some people switch back. Some move to the higher-dose Wegovy pen. Some stay the course and find the plateau resolves. Which path is right depends on clinical assessment, not general advice. Our prescribers at nume review each case individually, if you transferred your prescription to us, your consultation covers exactly this kind of situation. If you're considering starting fresh with clinical oversight, a free consultation is the right first step. Your pen, if treatment is approved, arrives the next working day by DPD in plain packaging, tracked to your door.

For context on how other patients navigate a similar stall, this piece on Mounjaro working well but Wegovy underperforming goes into the specific scenarios prescribers see most often. Which treatment suits your situation is a clinical decision our prescribers make with you, not a call anyone should make alone.